Blake T Aftab

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9105815/publications.pdf

Version: 2024-02-01

31	2,333	430874	610901
papers	citations	18 h-index	24 g-index

32	32	32	3928
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature, 2022, 603, 321-327.	27.8	343
2	Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis. Cancer Cell, 2015, 28, 653-665.	16.8	319
3	Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothened Antagonists. Cancer Cell, 2013, 23, 23-34.	16.8	296
4	Epsteinâ€“Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies. Trends in Molecular Medicine, 2020, 26, 296-310.	6.7	178
5	Itraconazole Inhibits Angiogenesis and Tumor Growth in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2011, 71, 6764-6772.	0.9	132
6	Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 619-623.	1.1	119
7	Validation of the Hsp70â€“Bag3 Proteinâ€“Protein Interaction as a Potential Therapeutic Target in Cancer. Molecular Cancer Therapeutics, 2015, 14, 642-648.	4.1	105
8	Epstein-Barr virusâ€“specific T cell therapy for progressive multiple sclerosis. JCI Insight, 2018, 3, .	5.0	105
9	The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma. Molecular Cancer Therapeutics, 2017, 16, 2375-2386.	4.1	90
10	A Polymeric Nanoparticle Encapsulated Small-Molecule Inhibitor of Hedgehog Signaling (NanoHHI) Bypasses Secondary Mutational Resistance to Smoothened Antagonists. Molecular Cancer Therapeutics, 2012, 11, 165-173.	4.1	77
11	Off-the-shelf VÎ´1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. , 2021, 9, e003441.		76
12	Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokineticâ€“Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor. Clinical Cancer Research, 2012, 18, 3090-3099.	7.0	74
13	Molecular signature of Epstein-Barr virus infection in MS brain lesions. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e466.	6.0	74
14	Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. Journal of Clinical Investigation, 2016, 126, 4640-4653.	8.2	74
15	Itraconazole Side Chain Analogues: Structureâ€“Activity Relationship Studies for Inhibition of Endothelial Cell Proliferation, Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Glycosylation, and Hedgehog Signaling. Journal of Medicinal Chemistry, 2011, 54, 7363-7374.	6.4	45
16	Allogeneic CD20â€targeted Î³Î´ T cells exhibit innate and adaptive antitumor activities in preclinical Bâ€cell lymphoma models. Clinical and Translational Immunology, 2022, 11, e1373.	3.8	42
17	Profiling HPV-16â€“specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients. Journal of Experimental Medicine, 2020, 217, .	8.5	37
18	CD46 Is Amplified in High-Risk Myeloma with Gain of Chromosome 1q and Selectively Targeted By a Novel Anti-CD46 Antibody-Drug Conjugate. Blood, 2016, 128, 384-384.	1.4	37

#	Article	IF	Citations
19	Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica, 2018, 103, 1218-1228.	3.5	30
20	Potent Activity of an Anti-ICAM1 Antibodyâ€“Drug Conjugate against Multiple Myeloma. Clinical Cancer Research, 2020, 26, 6028-6038.	7.0	20
21	Toward â€œoffâ€theâ€shelfâ€•allogeneic CAR T cells. Advances in Cell and Gene Therapy, 2020, 3, e86.	0.9	20
22	Genome-Scale Crispr-Cas9 Knockout Studies Reveal Mutifactorial and Functionally Overlapping Mechanisms of Myeloma Cell Resistance to Proteasome Inhibition. Blood, 2014, 124, 273-273.	1.4	16
23	Proteomeâ€wide analysis of Tâ€cell response to BK polyomavirus in healthy virus carriers and kidney transplant recipients reveals aÂunique transcriptional and functional profile. Clinical and Translational Immunology, 2020, 9, e01102.	3.8	11
24	Eight polymorphic microsatellite markers for kelp bass, Paralabax clathratus, amplified in three multiplex polymerase chain reaction sets. Molecular Ecology Notes, 2005, 5, 127-129.	1.7	4
25	Therapeutic potential of Hedgehog signaling inhibitors in cancer: rationale and clinical data. Clinical Investigation, 2012, 2, 371-385.	0.0	1
26	Defining Primary Marrow Microenvironment-Induced Synthetic Lethality and Resistance for 2,684 Approved Drugs Across Molecularly Distinct Forms of Multiple Myeloma. Blood, 2015, 126, 503-503.	1.4	1
27	Pre-Clinical Activity of the Novel, First-in-Class p97 Inhibitor, CB-5083, in Multiple Myeloma. Blood, 2014, 124, 4701-4701.	1.4	0
28	Temporal Dynamics of Tumor-Microenvironment Interaction and Treatment Responses Revealed through Time-Lapse Compartment-Specific Bioluminescence Imaging: Translational implications. Blood, 2014, 124, 276-276.	1.4	0
29	Functional Mapping of Multiple Myeloma Kinome Using a Small Molecule Inhibitor Library. Blood, 2014, 124, 3642-3642.	1.4	0
30	Constitutive Vs. Stroma-Induced Kinase Dependencies in Myeloma Cells: Functional Mapping Using Small Molecule Inhibitors As Chemical Probes. Blood, 2015, 126, 3709-3709.	1.4	0
31	Tofacitinib Reverses Growth Promoting Effects of the Bone Marrow Stromal Environment Though Inhibition of JAK1/STAT3 Signaling in Multiple Myeloma. Blood, 2016, 128, 2098-2098.	1.4	0